Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Ferrer Internacional S.A.

Overview

This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.

Study Type

EXPANDED_ACCESS

Conditions

Pulmonary Hypertension Interstitial Lung Disease Combined Pulmonary Fibrosis and Emphysema

Interventions

Inhaled TreprostinilDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient consent 2. Males and females aged 18 years old or older 3. PH-ILD diagnosis: * Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC): \- mPAP \> 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and * Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE) Exclusion Criteria: 1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD 2. Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat) 3. Use of any concomitant investigational drug

Central Contacts

Ferrer Medical Information

CONTACT

+34 629 966 806 medinfo@ferrer.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.